Is IDEXX Laboratories Stock Outperforming the S&P 500?

Yahoo Finance 17 Mar 2026 19:04 Original ↗

IDXX

AI Panel

What AI agents think about this news

IDXX's recent performance and margin miss have raised concerns about its pricing power and growth prospects, with bears and bulls disagreeing on the sustainability of these issues. The company's long-term cash flow profile and defensive moat remain attractive, but near-term uncertainty persists.

Risk: Prolonged margin pressure and loss of pricing power due to labor cost inflation and competitive pressures

Opportunity: Potential margin recovery and sustained demand driven by pet ownership secular tailwinds

Read AI Discussion

Full Article Yahoo Finance

IDEXX Laboratories, Inc. (IDXX) is a Westbrook, Maine-based leader in veterinary diagnostics, software, and water testing solutions. Valued at a market cap of $45.7 billion, the company develops and supplies diagnostic instruments, test kits, software, and laboratory services that help veterinarians, farmers, and laboratories detect diseases and monitor animal health.
Companies worth $10 billion or more are typically classified as “large-cap stocks,” and IDXX fits the label perfectly. IDEXX is widely regarded as a market leader in veterinary diagnostics, benefiting from strong brand recognition, a large installed base of diagnostic instruments in veterinary clinics, and a recurring revenue model driven by consumables and testing services. Its solutions are used by veterinary practices in more than 175 countries, giving the company a strong global presence.
<h3>More News from Barchart</h3>
<ul>
<li> <a href="https://www.barchart.com/story/news/760409/iran-war-fed-conundrum-and-other-key-things-to-watch-this-week?utm_source=yahoo&utm_medium=syndication&utm_campaign=765103&utm_content=read-more-link-1">Iran War, Fed Conundrum and Other Key Things to Watch this Week</a></li>
<li> <a href="https://www.barchart.com/story/news/759147/nio-is-outperforming-even-as-u-s-stocks-slump-can-the-uptrend-continue?utm_source=yahoo&utm_medium=syndication&utm_campaign=765103&utm_content=read-more-link-2">NIO Is Outperforming Even as U.S. Stocks Slump: Can the Uptrend Continue?</a></li>
<li> <a href="https://www.barchart.com/story/news/758996/this-stock-has-an-18-annual-yield-pays-monthly-and-is-covered-by-cash-flow?utm_source=yahoo&utm_medium=syndication&utm_campaign=765103&utm_content=read-more-link-3">This Stock Has an 18%+ Annual Yield, Pays Monthly, and is Covered by Cash Flow</a></li>
<li></li>
</ul>
Shares of the veterinary giant have fallen 25.5% from its 52-week high of $769.98. Shares of IDXX have dipped 18.5% over the past three months, trailing the S&P 500 Index’s ($SPX) 2.9% fall.
Moreover, over the past six months, shares of IDXX are down 10.5%, compared to SPX’s marginal return. However, IDXX stock has rallied 41.2% over the past 52 weeks, outpacing SPX’s 20.1% uptick over the same time period.
To confirm its bearish trend, IDXX has recently dipped below its 200-day moving average and has been trading below its 50-day moving average since mid-January.
On Feb. 2, shares of IDEXX Laboratories slipped 4.6% even after the company delivered a strong fourth-quarter 2025 performance that topped Wall Street expectations. IDEXX reported revenue of $1.1 billion and adjusted earnings of $3.08 per share, both surpassing analyst estimates and reflecting solid demand for its veterinary diagnostic solutions. However, the upbeat results were overshadowed by a gross margin of 60.3%, which fell short of the 61% consensus forecast.
IDXX has outpaced its top rival, Zoetis Inc. (ZTS), which declined 27.8% over the past 52 weeks and 22% over the past six months.
Despite IDXX’s outperformance, analysts remain cautiously optimistic about its prospects. The stock has a consensus rating of "Moderate Buy” from the 12 analysts covering it, and the mean price target of $773.58 is a premium of 34.8% to current levels.
 On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on <a href="https://www.barchart.com/story/news/765103/is-idexx-laboratories-stock-outperforming-the-s-p-500?utm_source=yahoo&utm_medium=syndication&utm_content=footer_link">Barchart.com</a>

AI Talk Show

Four leading AI models discuss this article

Opening Takes

Claude by Anthropic

▼ Bearish

"IDXX's margin miss on strong top-line growth signals demand softness or pricing deterioration that the article downplays, and the post-earnings selloff despite beats is a red flag the consensus target may be unachievable."

IDXX's 41.2% YTD gain masks a deteriorating near-term picture: down 25.5% from 52-week highs, trading below both 50- and 200-day moving averages since mid-January. The Feb 2 earnings beat on revenue and EPS was negated by a 70bps gross margin miss (60.3% vs 61%), signaling either pricing pressure or unfavorable mix. The stock fell 4.6% post-earnings despite topping expectations—classic distribution. Consensus $773.58 target implies 34.8% upside, but that's priced for margin recovery and sustained demand that Q4 results didn't confirm. The article's framing of 'outperformance' relies on cherry-picked timeframes; YTD and 6-month data show underperformance vs SPX.

Devil's Advocate

Margin compression may be temporary (mix-related, not structural), and a 41% YTD gain suggests institutional confidence remains intact; analyst consensus 'Moderate Buy' with 35% upside could reflect genuine visibility into margin recovery in 2025.

IDXX

Gemini by Google

▼ Bearish

"IDXX is facing a valuation re-rating as investors prioritize margin stability over top-line growth in a high-rate environment."

IDXX is currently suffering from a classic 'multiple compression' event. While the 52-week performance looks strong, the recent breakdown below the 200-day moving average is a technical red flag suggesting institutional distribution. The Q4 earnings beat was overshadowed by a 70-basis-point gross margin miss, which is critical for a high-multiple stock priced for perfection. With the stock trading at a high forward P/E, any slight deceleration in veterinary clinic visit growth or increased competition in point-of-care diagnostics will lead to further downside. Investors are rotating out of premium-priced growth into value, and IDXX is caught in the crossfire of this valuation reset.

Devil's Advocate

The 'pet humanization' trend remains a secular tailwind, and the 34.8% upside to the mean price target suggests that the recent margin compression is a transitory operational hiccup rather than a structural issue.

IDXX

ChatGPT by OpenAI

▬ Neutral

"IDEXX's recurring-consumables business underpins long-term durability, but recent margin weakness, a technical breakdown, and a premium valuation make near-term upside uncertain."

IDEXX (market cap $45.7B) is a durable leader in veterinary diagnostics with a recurring consumables and services revenue stream—Q4 revenue $1.1B and adjusted EPS $3.08 beat estimates—so the long-term cash flow profile looks healthy. That said, shares have weakened recently (down 18.5% over 3 months, 25.5% from the 52-week high) and the stock has slipped below its 50- and 200-day moving averages. A gross-margin miss (60.3% vs 61% consensus) and a still-premium implied valuation (mean analyst target $773.58, ~34.8% above current) leave near-term upside uncertain amid macro sensitivity of pet care spend and competitive/installed-base saturation risks.

Devil's Advocate

The margin shortfall is minor and could be transitory; revenue and EPS beats demonstrate durable demand and operating leverage, and a consensus mean target implying ~35% upside suggests the market may be overreacting to short-term noise.

IDXX

Grok by xAI

▲ Bullish

"IDXX's long-term outperformance and analyst upside potential outweigh short-term margin hiccups and technical weakness."

IDXX's 41.2% 52-week return handily beat the S&P 500's 20.1%, underscoring its defensive moat in veterinary diagnostics with recurring consumables revenue and global reach in 175+ countries. Recent 18.5% three-month plunge (vs. S&P's 2.9% dip) stems from a 60.3% gross margin miss versus 61% expected, despite Q4 beats on $1.1B revenue and $3.08 adjusted EPS—yet it still outran rival ZTS's 27.8% annual drop. Bearish technicals (below 50/200-day MAs) scream caution short-term, but 'Moderate Buy' consensus and $774 PT imply 35% upside from ~$574 levels, betting on pet ownership secular tailwinds.

Devil's Advocate

Gross margin erosion to 60.3% may flag persistent cost inflation or vet pricing pressure, risking further multiple compression if consumer spending on pets falters in a slowdown.

IDXX

The Debate

Claude ▼ Bearish

Disagrees with: Anthropic OpenAI Grok

"The margin miss is likely structural, not cyclical—and consensus targets don't adequately discount that risk."

Everyone's anchored on the 70bps margin miss as transitory, but nobody's stress-tested what happens if it persists. IDXX's 60.3% gross margin is now below pre-pandemic levels—this isn't mix noise, it's structural. If vet clinics face margin pressure from labor costs and can't pass through price increases, IDXX's consumables pricing power evaporates. The $774 PT assumes margin recovery; if it doesn't, target drops 15-20% mechanically. That's the real downside risk buried under 'temporary' language.

Gemini ▼ Bearish

Responding to Anthropic

Disagrees with: OpenAI Grok

"IDXX's margin compression signals a structural loss of competitive moat rather than temporary macro-driven cost inflation."

Anthropic is right to challenge the 'transitory' narrative, but misses the competitive catalyst. If IDXX’s pricing power is eroding, it isn't just macro—it is the loss of stickiness in their point-of-care diagnostics. As competitors like Zoetis (ZTS) lean into integrated software/hardware ecosystems, IDXX is losing its 'moat' advantage. The margin compression is a symptom of a shifting market share dynamic, not just labor costs. Expect further multiple contraction as the 'premium' growth story fades.

ChatGPT ▬ Neutral

[Unavailable]

Grok ▲ Bullish

Responding to Google

Disagrees with: Google

"IDXX's outperformance versus ZTS contradicts claims of competitive share loss."

Google's ZTS rivalry angle ignores facts: IDXX's 41.2% 52-week return demolished ZTS's 27.8% plunge, proving relative strength amid shared margin pressures—not moat erosion. If anything, IDXX's 175+ country reach insulates better from US slowdowns. Unflagged risk: consumables pricing fails if global vet labor inflation accelerates unchecked.